Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Co-Diagnostics, DocuSign, Dow, Nomura, Sea and more.
Tuesday's top analyst upgrades and downgrades included AECOM, BBVA, Cheniere Energy, Chevron, DraftKings, General Motors, Moderna, Novavax, Palo Alto Networks and Penn National Gaming.
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
Friday's top analyst upgrades and downgrades included AES, Applied Materials, Bloom Energy, Chimera Investment, Co-Diagnostics, FirstEnergy, Home Depot, Marriott, Target, Tesla and Walmart.
Investors look at Aytu BioScience as it looks at expanding in the COVID testing field.
Aytu BioScience has a distribution agreement for a COVID-19 rapid test and is developing a potential UV light-based treatment.
Wednesday's top analyst upgrades and downgrades included AbbVie, American Electric Power, Anheuser-Busch InBev, Arconic, Baidu, Best Buy, Co-Diagnostics, Cree, Exelon, Home Depot, NRG Energy, T-Mobile and Walmart.
Monday's top analyst upgrades and downgrades included Apple, Best Buy, Cinemark, Co-Diagnostics, DraftKings, Energizer, Novavax, Nvidia, Palo Alto Networks and Petrobras.
This specialty pharmaceutical company is making good progress on multiple fronts, including changes to its board of directors and with its test for and treatment of COVID-19.
Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.
Co-Diagnostics has been the toast of Wall Street after it went from penny stock status to a revered coronavirus testing stock.
GenMark Diagnostics shares shot up early on Wednesday after the company provided an update on its quarterly numbers and where it stands with its coronavirus test.
Co-Diagnostics shares popped on Monday after the company announced a key update from the FDA on its COVID-19 test kit.
Becton, Dickinson is officially throwing its hat in the ring to fight COVID-19. Specifically, this firm is working on the front end by testing for the disease and antibodies that have been…
